Literature DB >> 17427184

Identification of two risk haplotypes for schizophrenia and bipolar disorder in the synaptic vesicle monoamine transporter gene (SVMT).

Blanca Gutiérrez1, Araceli Rosa, Sergi Papiol, Francisco J Arrufat, Rosa Catalán, Purificación Salgado, Víctor Peralta, Manuel J Cuesta, Lourdes Fañanás.   

Abstract

The synaptic vesicular monoamine transporter (SVMT) plays a key role in monoaminergic neurotransmission determining the size of neurotransmitter vesicular pools available for exocytotic release. Recently, several lines of evidence have suggested that altered functions of SVMT may be involved in the pathogenesis of certain neuropsychiatric diseases, including psychotic and mood disorders. In the present study, we tested the potential involvement of SVMT gene variants in the etiology of schizophrenia and bipolar disorder. Five different SNPs (T440G, C1368T, T2666C, A2683C, and A745G) were included in the analysis covering a region of about 35 kb along the SVMT gene. Analyses were performed in a case-control sample consisting of 88 bipolar patients, 107 subjects with schizophrenia, and 164 controls. Two risk haplotypes for both schizophrenia and bipolar disorder in SVMT gene were identified. Particularly, 2666T-2683A-745G (TAG) and 2666C-2683C-745A (CCA) combinations were significantly more frequent in both bipolar and schizophrenic patients than in controls. UNPHASED package estimated haplotype effects for all patients yielded relative risks of 4.1 (95%CI: 1.83-9.21) for TAG combination and 2.336 (95%CI: 1.28-4.26) for CCA haplotype. Conversely, 2666T-2683C-745A (TCA) and 2666C-2683A-745G (CAG) haplotypes seemed to protect against these mental disorders, since the estimated frequency in control chromosomes was 12% whilst such haplotypes were not observed in any bipolar or schizophrenic subject (P < 0.0000). Our results strongly suggest that SVMT gene or certain regions of it may constitute a genetic substrate of susceptibility for both schizophrenia and bipolar disorder. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17427184     DOI: 10.1002/ajmg.b.30499

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  8 in total

1.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

2.  Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition.

Authors:  Claudia J P Simons; Ruud van Winkel
Journal:  Schizophr Bull       Date:  2012-04-24       Impact factor: 9.306

3.  Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences.

Authors:  Nicolas Narboux-Nême; Corinne Sagné; Stephane Doly; Silvina L Diaz; Cédric B P Martin; Gaelle Angenard; Marie-Pascale Martres; Bruno Giros; Michel Hamon; Laurence Lanfumey; Patricia Gaspar; Raymond Mongeau
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 4.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

5.  Association between polymorphisms in the vesicle-associated membrane protein-associated protein A (VAPA) gene on chromosome 18p and bipolar disorder.

Authors:  Falk W Lohoff; Andrew E Weller; Paul J Bloch; Aleksandra H Nall; Thomas N Ferraro; Wade H Berrettini
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575

6.  Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia.

Authors:  Makoto Kinoshita; Shusuke Numata; Atsushi Tajima; Shinji Shimodera; Issei Imoto; Tetsuro Ohmori
Journal:  Epigenetics       Date:  2013-04-26       Impact factor: 4.528

Review 7.  SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine.

Authors:  Hakeem O Lawal; David E Krantz
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

8.  Bipolar Disorder and the TCI: Higher Self-Transcendence in Bipolar Disorder Compared to Major Depression.

Authors:  James A Harley; J Elisabeth Wells; Christopher M A Frampton; Peter R Joyce
Journal:  Depress Res Treat       Date:  2011-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.